<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">We administered lopinavir to moderate to severe cases for 5Â days. Clinical trials demonstrated its effectiveness in the treatment of patients with SARS and MERS [
 <xref ref-type="bibr" rid="CR11">11</xref>]. Molecular analysis indicates that lopinavir has a potential role in inhibiting SARS-CoV-2 protease, thereby blocking viral replication [
 <xref ref-type="bibr" rid="CR12">12</xref>]. A recent study found a limited benefit of lopinavir compared with the standard of care treatment [
 <xref ref-type="bibr" rid="CR13">13</xref>]. However, this study had substantial methodologic limitations, which raises questions about its conclusions.
</p>
